Eli Lilly (LLY)
Health Care
Eli Lilly and Company is an American pharmaceutical company with offices in 18 countries. Lilly's notable achievements include being the first company to mass produce the polio vaccine developed by Jonas Salk and insulin.
Companies are assessed against the expectations laid out in the 2020 Ceres Blueprint for Responsible Policy Engagement on Climate Change. Assessments evaluate companies' climate change risk assessment, governance, advocacy, and engagement practices, and can be used to gain a deeper understanding of their systems and performance on responsible policy engagement on climate change. Investors can use the information provided to engage their portfolio companies on both the risks and opportunities associated with climate lobbying practices.
Meets Expectations
Does not meet expectations
Yes
Unclear
No
Not Applicable
Eli Lilly's performance
Responsible Policy Engagement Public Company Assessment 2021
Last Updated
08 July 2021 - 00:46
The company's 10-K recognized the physical risks of climate change as a material risk
The company's 10-K recognized the transition risks associated with climate change as a material risk
The board has assigned formal oversight of climate change and/or sustainability to one or more standing committees
The company has publicly affirmed the science of climate change
The company has made statements supporting the need for ambitious climate policies
The company has publicly supported the Paris Climate Agreement
The company has publicly joined a group of companies to advocate for specific science-based climate policies
The company has publicly and individually advocated for specific science-based climate policies
The company has not engaged in opposition to science-based climate policies
The company has disclosed a list of its trade association memberships
The company has conducted an audit of its trade associations for science-based climate policy alignment
The company is a member of the U.S. Chamber of Commerce
If a member of the Chamber, the company has disclosed its understanding that the Chamber has a record of lobbying in misalignment with climate science
If a member of the Chamber, the company has disclosed its engagements to evolve the Chamber’s climate change positions and lobbying
